Ocul Surf
-
Publication Venue For
- Fluorescein CorneoGraphy (FCG): Use of a repurposed fluorescein imaging technique to objectively standardize corneal staining.. 27:77-79. 2023
- Exposure keratopathy in patients undergoing invasive ventilation: Prevalence, severity, and the role of surface lubrication.. 25:55-57. 2022
- Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model.. 21:271-278. 2021
- Matrix metalloproteinase 9 positivity predicts long term decreased tear production.. 19:270-274. 2021
- Association of meibomian gland architecture and body mass index in a pediatric population.. 18:657-662. 2020
- Corrigendum to "TFOS DEWS II pathophysiology report" [Ocul. Surf. 15 (3) (2017) 438-510].. 17:842. 2019
- Incidence and risk factors of symptomatic dry eye disease in Asian Malays from the Singapore Malay Eye Study.. 15:742-748. 2017
- Role of high resolution optical coherence tomography in diagnosing ocular surface squamous neoplasia with coexisting ocular surface diseases.. 15:688-695. 2017
- TFOS DEWS II iatrogenic report.. 15:511-538. 2017
- TFOS DEWS II pathophysiology report.. 15:438-510. 2017
- Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease.. 14:168-188. 2016
- Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.. 14:207-215. 2016
- The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.. 14:189-195. 2016
- Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease.. 14:2-19. 2016
- Treatment of blepharitis: recent clinical trials.. 12:273-284. 2014